STE · 10-Q · 2026Q3 · Full report

Portfolio and Organizational Optimization

STERIS plc · 2026-11-05 · Importance 46 · Surprise 42 · In source text

During the second quarter of fiscal 2027, STERIS approved a targeted plan covering facility realignment, product rationalization, and organizational realignment. The company anticipates approximately $45 million in charges, comprising about $10 million of cash expenditures and $35 million of non-cash charges, primarily asset impairment. The plan primarily relates to the Healthcare segment and is expected to be substantially complete by the end of fiscal 2028. STERIS had recorded $25.0 million of related restructuring expense, including $6.3 million in cost of revenues.

Key facts

• STERIS anticipates approximately $45 million of charges for its Fiscal 2027 Portfolio and Organizational Optimization Plan, including approximately $10 million in cash expenditures and $35 million in non-cash charges; the plan is expected to be substantially complete by the end of fiscal 2028. source
• STERIS expects to incur approximately $50 million to $60 million in cash expenditures for its open restructuring plans, substantially completed by fiscal 2030. source
• STERIS approved the Fiscal 2027 Portfolio and Organizational Optimization Plan during the second quarter of fiscal 2027, covering targeted facility, product and organizational realignment. source
• STERIS recorded $109.5 million of restructuring expense for the Fiscal 2025 Plan since inception, including $33.9 million in cost of revenues; execution was substantially complete as of March 31, 2026. source
• STERIS recorded $25.0 million of expense for the Fiscal 2027 Portfolio and Organizational Optimization Plan, including $6.3 million recorded in cost of revenues. source
• STERIS's Fiscal 2025 Plan included a strategic shift in its European Healthcare surgical business, impairment of an internally developed X-ray accelerator, product rationalizations and facility consolidations; approximately 300 positions were eliminated. source
• STERIS identifies the risk that anticipated financial results, revenues, productivity improvements, cost savings, growth synergies, and other acquisition, restructuring, and divestiture benefits may not be realized or may be lower than anticipated due to liabilities, impairments, or integration costs and difficulties. source

Impact estimates